2022
Pleiotropic MLLT10 variation confers risk of meningioma and estrogen-mediated cancers
Walsh KM, Zhang C, Calvocoressi L, Hansen HM, Berchuck A, Schildkraut JM, Bondy ML, Wrensch M, Wiemels JL, Claus EB. Pleiotropic MLLT10 variation confers risk of meningioma and estrogen-mediated cancers. Neuro-Oncology Advances 2022, 4: vdac044. PMID: 35702670, PMCID: PMC9187056, DOI: 10.1093/noajnl/vdac044.Peer-Reviewed Original ResearchRisk of meningiomaOvarian cancerBreast cancerER- breast cancerEstrogen receptor statusBody mass indexFemale breast cancerRisk of tumorsReceptor statusMass indexEstrogenic mechanismsHormonal factorsGenome-wide association studiesMeningiomasNormal meningesCancerMinor alleleCase-control datasetUK BiobankExpression quantitative trait lociMeningesRiskTumorsBreastAdiposity traits
2021
A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer
Wu YL, Tsuboi M, John T, Grohe C, Majem M, Goldman JW, Laktionov K, Kim SW, Kato T, Vu HV, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Hodge R, Atasoy A, Rukazenkov Y, Herbst RS. A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer. Future Oncology 2021, 17: 4827-4835. PMID: 34723634, DOI: 10.2217/fon-2021-0752.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerCell lung cancerClinical studiesADAURA studyLung cancerPost-surgery chemotherapyTypes of NSCLCRisk of tumorsPrevious clinical studiesCentral nervous systemEpidermal growth factor receptorEarly-stage EGFRGrowth factor receptorNCT numberActivity of EGFROsimertinib treatmentNSCLC tumorsSpinal cordTumor removalNSCLCSide effectsNervous systemOsimertinibPatientsSurgery
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply